Compare Appian Corp (APPN) vs Novo Nordisk A/S (NVO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Appian Corp vs Novo Nordisk A/S — how do they compare? Appian Corp trades at $35.5 (market cap $2.54B), while Novo Nordisk A/S trades at $46.49 (market cap $207.85B). The key difference: Novo Nordisk A/S is far larger — about 81.8× Appian Corp's market cap, and Novo Nordisk A/S pays a 3.81% dividend while Appian Corp pays none. Which is the better fit depends on your goals.
| APPN | NVO | |
|---|---|---|
Market Cap | $2.54B | $207.85B |
Sector | Technology | Health |
52-Week High | $45.64 | $63.98 |
52-Week Low | $18.72 | $35.29 |
Enterprise Value | $2.67B | $222.55B |
Dividend Yield | — | 3.81% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Appian (APPN) trades at $34.82, down 2.14% on the day despite strong technical momentum. The stock shows bullish moving average signals but overbought RSI readings. Fundamentally, the company delivered three consecutive earnings beats with Q2 2026 EPS of $0.13 beating expectations of $0.00308, while revenue grew 19% year-over-year to $203.3 million. Recent news highlights AI-powered underwriting partnerships and strong enterprise demand driving growth.
Appian presents a mixed investment case with strong revenue growth and AI momentum offset by negative profitability metrics and elevated valuations. The stock trades above analyst consensus target of $32.50, suggesting limited near-term upside. Key risks include persistent negative ROE (-936.62%) and high debt levels, though improving cash flow and AI adoption provide growth catalysts.
Novo Nordisk (NVO) trades at $46.465, down 2.65% today, with a neutral technical signal. The stock shows strong fundamentals, including a P/E of 11.62, net income margin of 35.35%, and consistent earnings beats in recent quarters. Recent news highlights competitive pressures from Eli Lilly and mixed investor reactions to Q2 2026 results, despite an upwardly revised full-year outlook.
Outlook remains positive due to robust GLP-1 drug demand and profitability, but risks include pricing pressure and competition. Analysts are predominantly bullish (57.9% buy ratings), supporting a favorable long-term view despite near-term volatility.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Appian Corp
Appian Corp provides a low-code software development platform as a service that enables organizations to rapidly develop powerful and unique applications. With its platform, organizations can rapidly and easily design, build and implement powerful, enterprise-grade custom applications through intuitive, visual interface with little or no coding required. The company's customers use applications built on its low-code platform to launch new business lines, automate vital employee workflows, manage complex trading platforms, accelerate drug development and build procurement systems. The group generates a majority of its revenue from the domestic market. It serves various industries such as education.
Read more on APPN →About Novo Nordisk A/S
With almost 50% market share by volume of the global insulin market, Novo Nordisk is the leading provider of diabetes-care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments, and oral antidiabetic agents. Novo also has a biopharmaceutical segment (constituting roughly 15% of revenue) that specializes in protein therapies for hemophilia and other disorders.
Read more on NVO →
